Ipilimumab (Yervoy ®) is a fully human anti human IgG1 monoclonal antibody and an immune-modulatory agent that has been developed for the treatment of cancer.


PPS has generated considerable experience in the analysis of different originator batches as well as variants of biosimilars of Ipilimumab.


We have established an analytical program according to the ICH Q6B guidance, including the method setup, validation of customer specific methods and release testing.


This package includes different assays for protein quantification and characterizing the protein primary structure and secondary structure, as well as detailed analysis of N-glycosylation and protein modification.

 

Your contact for Ipilimumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100
Email: salesproteinservices@ProtagenProteinServices.com